Literature DB >> 16303245

Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.

Masayoshi Imura1, Satoshi Yamashita, Li-Yi Cai, Jun-Ichi Furuta, Mika Wakabayashi, Toshiharu Yasugi, Toshikazu Ushijima.   

Abstract

Aberrant methylation of CpG islands (CGIs) in promoter regions of tumor-suppressor genes causes their silencing, and aberrant demethylation of normally methylated CGIs in promoter regions causes aberrant expression of cancer-testis antigens. Here, we comprehensively analyzed aberrant methylation of 15 genes and demethylation of three normally methylated genes in 13 ovarian cancer cell lines. RASSF1A was most frequently methylated (complete methylation in 7 and partial methylation in 4 cell lines), followed by ESR1 (5 and 2, respectively), FLNC (4 and 4), HAND1 (4 and 2), LOX (3 and 2), HRASLS (3 and 2), MGMT (3 and 0), CDKN2A (3 and 0), THBD (2 and 1), hMLH1 (2 and 0), CDH1 (1 and 1) and GSTP1 (1 and 0). hTERC and TIMP3 were only partially methylated in 7 and 2 cell lines, respectively. BRCA1 was not methylated at all. Aberrant demethylation of MAGE-A3, -B2 and -A1 was detected in 8, 4 and 3 cell lines, respectively. Gene expression was consistently absent in cell lines without unmethylated DNA molecules. Aberrant methylation was frequently observed in MCAS, RMUG-L (mucinous cell carcinomas), RTSG (poorly-differentiated carcinoma) and TYK-nu (undifferentiated carcinoma) while infrequent in HTOA, JHOS-2, and OV-90 (serous cell carcinomas). Aberrant demethylation was frequently observed in OV-90, OVK-18, and ES-2 cell lines. It was shown that aberrant methylation and demethylation were frequently observed in ovarian cancer cell lines, and these data will provide a basis for further epigenetic analysis in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303245     DOI: 10.1016/j.canlet.2005.10.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

2.  Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.

Authors:  Sabrina L Samudio-Ruiz; Laurie G Hudson
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

3.  Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.

Authors:  Jiaze An; Qingyi Wei; Zhensheng Liu; Karen H Lu; Xi Cheng; Gordon B Mills; Li-E Wang
Journal:  Int J Mol Epidemiol Genet       Date:  2010

4.  Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Authors:  Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics.

Authors:  Simon Kaja; Jill D Hilgenberg; Julie L Collins; Anna A Shah; Debra Wawro; Shelby Zimmerman; Robert Magnusson; Peter Koulen
Journal:  J Biomed Opt       Date:  2012-08       Impact factor: 3.170

6.  A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Authors:  Amit M Oza; Ursula A Matulonis; Angeles Alvarez Secord; John Nemunaitis; Lynda D Roman; Sarah P Blagden; Susana Banerjee; William P McGuire; Sharad Ghamande; Michael J Birrer; Gini F Fleming; Merry Jennifer Markham; Hal W Hirte; Diane M Provencher; Bristi Basu; Rebecca Kristeleit; Deborah K Armstrong; Benjamin Schwartz; Patricia Braly; Geoff D Hall; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Yong Hao; Harold Keer; Mohammad Azab; Daniela Matei
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

7.  An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma.

Authors:  A James Watkins; Rifat A Hamoudi; Naiyan Zeng; Qingguo Yan; Yuanxue Huang; Hongxiang Liu; Jianzhong Zhang; Esteban Braggio; Rafael Fonseca; Laurence de Leval; Peter G Isaacson; Andrew Wotherspoon; Ellen D McPhail; Ahmet Dogan; Ming-Qing Du
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  An alkylphenol mix promotes seminoma derived cell proliferation through an ERalpha36-mediated mechanism.

Authors:  Hussein Ajj; Amand Chesnel; Sophie Pinel; François Plenat; Stephane Flament; Helene Dumond
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.

Authors:  Hao Shi; Ya Li; Xiaozhong Wang; Cheng Lu; Lilan Yang; Changmei Gu; Jiaqiang Xiong; Yangxin Huang; Shixuan Wang; Meixia Lu
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

10.  Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Authors:  Ashley H Birch; Suzanna L Arcand; Kathleen K Oros; Kurosh Rahimi; A Kevin Watters; Diane Provencher; Celia M Greenwood; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.